Shuichi Hironaka

机构：Kyorin University · ORCID：0000-0001-9714-231X

发表论文 258 篇 · 总被引 10809 次 · h-index 42

代表论文

• Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer (2025 · Journal of Clinical Oncology · 被引 15)
• Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS (2024 · Gastric Cancer · 被引 7)
• Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan (2026 · EClinicalMedicine · 被引 4)
• Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab (2024 · International Journal of Clinical Oncology · 被引 4)
• First-Line Docetaxel Once Every 2 Weeks With Cisplatin Plus Fluorouracil for Metastatic Esophageal Cancer: A Multicenter, Randomized Controlled Phase III Study (JCOG1314, MIRACLE) (2025 · JCO oncology advances. · 被引 2)
• A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G) (2025 · Cancer · 被引 2)